Table 3.
Patients characteristics
| Characteristics | N | % |
|---|---|---|
| Patient age, median (range) | 51 (12–71) | |
| Patient gender | ||
| Male | 14 | 51.85 |
| Female | 13 | 48.15 |
| Relapse | 10 | 37.04 |
| Refractory | 17 | 62.96 |
| Diagnosis (WHO) | ||
| M1 | 0 | 0 |
| M2 | 4 | 14.81 |
| M4 | 8 | 29.63 |
| M5 | 12 | 44.44 |
| M6 | 2 | 7.41 |
| unavailable | 1 | 3.71 |
| Hb, ×g/L median (range) | 96 (71–120) | |
| WBC, ×109/L median (range) | 3.95 (1.40–49.13) | |
| Platelets, × 109/L median (range) | 101 (16–226) | |
| BM blasts median (range) | 27.6 (2.50–97.0) | |
| karyotype-risk (n=)a | ||
| Favorable-risk | 7 | 25.93 |
| Intermediate-risk | 1 | 3.70 |
| Poor-risk | 9 | 33.33 |
| Unavailable | 10 | 37.04 |
| DNMT3A mutational status | ||
| Wild-type DNMT3A | 18 | 66.67 |
| DNMT3Amutation | 3 | 11.11 |
| Missing | 6 | 22.22 |
| TP53 mutational status | ||
| Wild-type TP53 | 19 | 70.37 |
| TP53 mutation | 2 | 7.41 |
| Missing | 6 | 22.22 |
| FLT3-ITD mutational status | ||
| Wild-type FLT3-ITD | 18 | 66.67 |
| FLT3-ITD mutation | 3 | 11.11 |
| Missing | 6 | 22.22 |
| BCOR mutational status | ||
| Wild-type BCOR | 20 | 74.08 |
| BCOR mutation | 1 | 3.70 |
| Missing | 6 | 22.22 |
| NRAS mutational status | ||
| Wild-type NRAS | 19 | 70.37 |
| NRAS mutation | 2 | 7.41 |
| Missing | 6 | 22.22 |
| STAG2 mutational status | ||
| Wild-type STAG2 | 20 | 74.08 |
| STAG2 mutation | 1 | 3.70 |
| Missing | 6 | 22.22 |
Abbreviations: BM bone marrow, WBC white blood count, HB hemoglobin, PLT Platelet
aCytogenetic groups were defined as follows: favourable – t(8;21), inv. (16), irrespective of the presence of other abnormalities; adverse – monosomy5, monosomy 7, del(5q), abnormal 3q, complex (5 or more chromosomal abnormalities); intermediate – all other abnormal karyotypes, normal karyotype